ROCHE REMAINS A BELLWETHER, DESPITE RECENT (R&D) JITTERS (ADD; 14% UPSIDE)
19/09/22 -" Since early 2022, an already fragile global economy (surfing on monetary excesses) has faced several challenges – spiralling inflation and supply-chain disruptions – due to the war in Europe, ..."
Pages
69
Language
English
Published on
19/09/22
You may also be interested by these reports :
20/11/26
Sanofi’s ‘media-reported’ big acquisitive move can be a credible solution to growth concerns after lynchpin Dupixent loses exclusivity starting in ...
18/11/26
Leaving aside the mid-term profitability outlook downgrade in 2024, Lundbeck has often exceeded expectations with its operational delivery in the ...
17/11/26
In the last couple of years, most of Roche’s peers – including Novartis, AstraZeneca, Novo Nordisk and Sanofi – have suffered important R&D setbacks, ...
17/11/26
The factors discussed in the justification for DCF valuation have also prompted an upgrade to our NAV valuation. As a result, the target price resets ...